Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD | MicrobiomeTrials← Back to trialsNCT07877272
Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-10-05Est. Completion: 2028-04-01
Enrollment target: 500 participants Locations- University Hospital Muenster, Münster, Germany
Other microbiome trials you might be interested in
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease calle…
Tucson, United StatesEst. completion Jan 29, 2029
MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseMASH - Metabolic Dysfunction-Associated SteatohepatitisLiver Fibrosis/NASH
The goal of this clinical trial is to learn how physical exercise affects liver health in adults with metabolic dysfunct…
Madrid, SpainEst. completion Jun 2027
Metabolic Associated Fatty Liver DiseaseMetabolic Associated Steatotic Liver DiseaseCirrhosis, LiverNASHLiver FibrosisLiver FatLiver SteatosesLiver Inflammation
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effo…
Miami, United StatesEst. completion Jun 30, 2027